PACB
Pacific Biosciences of California, Inc.NASDAQHealthcare$1.34-0.74%ClosedMarket Cap: $404.7M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
75.63
P/S
2.53
EV/EBITDA
-6.87
DCF Value
$-11.00
FCF Yield
-30.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
28.2%
Operating Margin
-346.1%
Net Margin
-341.5%
ROE
-1123.3%
ROA
-121.1%
ROIC
-75.9%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $44.6M | 37.5% | $-41.2M | $-40.4M | $-0.13 | — |
| FY 2025 | $160.0M | 31.7% | $-557.6M | $-546.4M | $-1.82 | — |
| Q3 2025 | $38.4M | 39.2% | $-38.8M | $-38.0M | $-0.13 | — |
| Q2 2025 | $39.8M | 36.9% | $-44.9M | $-41.9M | $-0.14 | — |
| Q1 2025 | $37.2M | -3.7% | $-428.9M | $-426.1M | $-1.44 | — |
| Q4 2024 | $39.2M | 25.6% | $-153.0M | $2.4M | $0.01 | — |
| FY 2024 | $154.0M | 24.2% | $-474.3M | $-309.9M | $-1.07 | — |
| Q3 2024 | $40.0M | 25.0% | $-64.1M | $-60.7M | $-0.22 | — |
| Q2 2024 | $36.0M | 16.5% | $-175.8M | $-173.3M | $-0.64 | — |
| Q1 2024 | $38.8M | 29.1% | $-81.4M | $-78.2M | $-0.29 | — |
| Q4 2023 | $58.4M | 16.4% | $-87.5M | $-82.0M | $-0.31 | — |
| FY 2023 | $200.5M | 26.3% | $-334.5M | $-306.7M | $-1.21 | — |